{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:31:21Z","timestamp":1780500681138,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20064"],"award-info":[{"award-number":["P20064"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["P46908"],"award-info":[{"award-number":["P46908"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.vaccine.2015.05.059","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T21:15:31Z","timestamp":1433538931000},"page":"3746-3751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia"],"prefix":"10.1016","volume":"33","author":[{"given":"Ilaria","family":"Dorigatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Aguas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christl A.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Coudeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.05.059_bib0155","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2015.05.059_bib0160","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QCO.0b013e32834a1b0b","article-title":"Critical issues in dengue vaccine development","volume":"24","author":"Thomas","year":"2011","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.05.059_bib0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biotechadv.2010.11.008","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011","journal-title":"Biotechnol Adv"},{"issue":"7361","key":"10.1016\/j.vaccine.2015.05.059_bib0170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature10355","article-title":"The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations","volume":"476","author":"Walker","year":"2011","journal-title":"Nature"},{"issue":"7361","key":"10.1016\/j.vaccine.2015.05.059_bib0175","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nature10356","article-title":"Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission","volume":"476","author":"Hoffmann","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0180","first-page":"162","article-title":"Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children","volume":"3","author":"Tran","year":"2012","journal-title":"J Vaccines Vaccin"},{"issue":"9","key":"10.1016\/j.vaccine.2015.05.059_bib0185","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4161\/hv.21224","article-title":"Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2\u201345 years: Phase II randomized controlled trial in Singapore","volume":"8","author":"Leo","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"41","key":"10.1016\/j.vaccine.2015.05.059_bib0190","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2\u201311 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"issue":"9853","key":"10.1016\/j.vaccine.2015.05.059_bib0195","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0305","article-title":"First experience of concomitant vaccination against dengue and MMR in toddlers","volume":"8","author":"Crevat","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2015.05.059_bib0200","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1016\/j.vaccine.2015.05.059_bib0205","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9\u201316 year olds: a randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2015.05.059_bib0210","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2015.05.059_bib0215","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/382280","article-title":"Relationship of preexisiting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand","volume":"189","author":"Endy","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0220","series-title":"Model selection and multimodel inference: a practical information\u2014theoretic approach","author":"Burnham","year":"2002"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0225","series-title":"Applied multivariate statistical analysis","author":"Johnson","year":"1988"},{"issue":"5","key":"10.1016\/j.vaccine.2015.05.059_bib0230","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance","volume":"81","author":"Thomas","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2015.05.059_bib0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1471-2334-12-233","article-title":"Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis","volume":"12","author":"Rainwater-Lovett","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.05.059_bib0240","first-page":"e2952","volume":"8","author":"Salje","year":"2014","journal-title":"Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development"},{"issue":"4","key":"10.1016\/j.vaccine.2015.05.059_bib0245","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4269\/ajtmh.2010.10-0262","article-title":"Surveillance for Japanese encephalitis in Vietnam, 1998\u20132007","volume":"83","author":"Yen","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2015.05.059_bib0250","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/infdis\/148.6.1055","article-title":"Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status","volume":"148","author":"Scott","year":"1983","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.05.059_bib0255","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4049\/jimmunol.77.5.352","article-title":"Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses","volume":"77","author":"Schlesinger","year":"1956","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (chimerivax-den2) vaccine: phase I clinical trial for safety and immunogenicity","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2015.05.059_bib0265","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","article-title":"Evaluation of interferences between dengue vaccine serotypes in a monkey model","volume":"80","author":"Guy","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2015.05.059_bib0270","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.05.059_bib0275","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1016\/j.vaccine.2015.05.059_bib0280","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.4161\/21645515.2014.972131","article-title":"Assessment of bivalent and tetravalent dengue vaccine formulations in flavirvirus-na\u00efve adults in Mexico","volume":"10","author":"Dayan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2015.05.059_bib0285","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0290","series-title":"The world's first, large-scale dengue vaccine efficacy study successfully achieved its primary clinical endpoint","author":"Sanofi Pasteur","year":"2014"},{"issue":"9951","key":"10.1016\/j.vaccine.2015.05.059_bib0295","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.05.059_bib0300","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15007227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15007227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T01:14:46Z","timestamp":1691716486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15007227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":31,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0264410X15007227"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.059","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725541035.793512555","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}